"British scientists conducting earlystage research have found that a potential new drug from GlaxoSmithKline could treat mixedlineage leukemiaMLL  the most common form of leukemia in babies.  Signage is pictured on the company headquarters of GlaxoSmithKline in west London July  . REUTERSToby Melville In a study published in the journal Nature scientists from the British drugmaker collaborating with the charity Cancer Research UK CRUK and Cellzome AG found that the experimental drug called IBET mimics a chemical tag which is key to preventing the process of activating the leukemia genes.  This ... is an exciting new avenue for drug discovery which we hope will be useful for other types of cancer in addition to MLLleukaemias said Tony Kouzarides of the Wellcome TrustCRUK Gurdon Institute at Cambridge University who coled the study.  Kevin Lee head of epigenetics discovery research at GSK who also worked on the study said he too was excited about the findings although it will probably be many years before the drug could potentially reach the market.  Even though this is still labbased ... it validates the idea of developing small molecules against epigenetic switches he said in an emailed comment.  It is important to remember we will need to be successful on a number of additional steps before we can move this from the lab to testing this compound in humans.  MLL leukemia is thought to account for up to  percent of cases of acute leukemia in children below two years old and up to one in  cases in adults.  Most patients dont respond well to standard leukemia treatments and often the cancer comes back.  The disease is caused when a gene called MLL gets fused to another gene. This disrupts the normal function of MLL by creating a new fusion protein that behaves wrongly switching on genes that drive the development of leukemia.  Kouzaridess team found that in the disease the MLLfusion proteins are targeted to leukemiacausing genes by proteins from the BET family which recognize certain chemical tags on chromatin the scaffold on which DNA is arranged.  Using IBET to treat leukaemias in mice and human cancer cells in a lab the researchers found that the chemical could halt the disease paving the way for more research to be done in firststage or socalled Phase I human trials.  We urgently need better ways to treat children with more aggressive forms of leukemia such as MLL said Lesley Walker CRUKs director of information.  Although this research is only in the lab at the moment we hope it will move quickly toward clinical trials in patients.  Leukemia is the most commonly diagnosed cancer in children and accounts for a around a third of all cancers diagnosed in children. According to Cancer Research UK eight out of  children with leukemia in Britain now survive for five years or more compared with one in  in the late s.  Editing by Sugita Katyal Our StandardsThe Thomson Reuters Trust Principles. httpthomsonreuters.comenaboutustrustprinciples.html"